Oppenheimer raises its price target for Questcor Pharma (QCOR +3%) to $69 from $59 after...
Tuesday, September 18, 2012, 9:34 AM ETOppenheimer raises its price target for Questcor Pharma (QCOR +3%) to $69 from $59 after positive commentary from investor meetings. Investors are becoming more comfortable with QCOR's perceived risks, the firm says, and any additional negative reports will result in limited downside volatility. Acthar reimbursement rates remain “extremely strong,” the firm adds.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles